Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $23.489M Beat $17.545M Estimate
Portfolio Pulse from Benzinga Newsdesk
Nektar Therapeutics (NASDAQ:NKTR) reported Q2 2024 GAAP EPS of $(0.25), missing the analyst estimate of $(0.21) by 19.05%. However, the company reported sales of $23.489 million, beating the estimate of $17.545 million by 33.88% and showing a 14.59% increase from the same period last year.
August 08, 2024 | 9:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Nektar Therapeutics reported a Q2 2024 GAAP EPS of $(0.25), missing the analyst estimate of $(0.21) by 19.05%. However, the company reported sales of $23.489 million, beating the estimate of $17.545 million by 33.88% and showing a 14.59% increase from the same period last year.
The mixed earnings report, with a significant EPS miss but a strong sales beat, creates a neutral short-term outlook for NKTR. The sales beat and year-over-year growth are positive, but the EPS miss may weigh on investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100